Translational relevance
The hedgehog pathway has a critical role in the development of pancreatic cancer.The paracrine loop between cancer cells and stellate cells provide support for proliferation, spreading capacities and treatment resistance of pancreatic cancer cells. In the present study, we found that Shh and Gli1 protein expression were independent prognosticators for the disease-free and the overall survival in resected pancreatic cancer. The combination of those biomarkers is more informative than the classical prognostic factors (stage, lymph nodes status). Importantly, two independent multicentric validations cohorts replicated those results.
Our results suggest that Shh and Gli1 expression could be tested in a molecular-driven study as a "companion diagnostic" for anti-Shh and anti-Gli1 targeted therapies.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid malignancies with a 5-year survival rate of < 5% (1) . This highly invasive disease is characterized by an extensive desmoplastic reaction. The epithelial and stromal compartments interact to enhance the aggressive nature of this cancer by fostering tumor growth, angiogenesis, metastatic spread and enhancing drug resistance (2) . Recent studies in multiple pancreatic cancer models have implicated the hedgehog (Hh) signaling pathway in these tumor-stromal interactions (3) (4) (5) (6) (7) .
Response to the Hh signaling proteins (Sonic hedgehog (Shh), Indian hedgehog (Ihh) and desert hedgehog (Dhh)) is regulated by the receptor Patched (PTCH), that repress the activity of the transducer protein smoothened (SMO). Hh protein binds PTCH1 and blocks its inhibition of SMO inducing activation of the Gli family of transcription factorsincluding Gli1 and PTCH1. Constitutive activation of the pathway by activating mutations in SMO or inactivating mutations in the tumor suppressor gene PTCH leads to cell proliferation and tumor formation (8) (9) (10) . Such mutations have not been described in PDAC but overexpression of the Shh ligand has been reported to occur in 70% of primary PDAC and has been implicated in the development and the progression of pancreatic tumors (11, 12) . A paracrine Hh signaling is reversed in PDAC with tumor cells secreting Shh that activate signaling within stromal cells to produce secondary factors supporting angiogenesis and tumor cell proliferation and survival (3) (4) (5) (6) (7) (13) (14) (15) (16) (17) . These data support a functionally important role for Hh signaling in PDAC tumorigenesis. Surprisingly, Gli expression within the pancreatic tumor epithelium is maintained despite SMO deletion and does not correlate with Hh ligand levels (7), suggesting a more complex regulation of the pathway. KRAS and TGF-β, two signaling pathway prominently involved in PDAC tumorigenesis, regulate the SMO-independent expression of Gli1 target genes in mouse PDAC cells (7, 18) . Furthermore, Gli1 expression facilitates the migration and invasion of PDAC cell lines and is required for KRAS-mediated cellular transformation (19, 20 Although aberrant Hh signaling has been found to affect pancreatic cancer behavior, correlation between the hedgehog pathway components and patients outcome has not yet been evaluated.
The purpose of this study is to determine whether Gli1, Shh, PTCH1 and SMO expression within tumors have any relationship with the clinical outcome of the patients (prognostic value) and the benefit of adjuvant therapy (predictive value) in PDAC patients who underwent a curative-intent surgery. 
PATIENTS AND METHODS

Patients and Data Study Design
Specimen characteristics and Tissue Microarray
Fixation of tumor specimens followed standard protocols, using either 10% non buffered or 10% buffered formalin for 12 hours, dehydrated in 70% EtOH and paraffin embedded. FFPE PDACs were stored at room temperature. Tissue microarrays (TMAs) were constructed from 0.6-mm tissue cores obtained from FFPE with each tumor represented by 3-5 cores. H&E staining was performed on each TMA slide to confirm tumor presence.
Gli1, PTCH1, SMO and Shh immunohistochemistry
Immunostaining was done using the following antibodies and concentrations: rabbit anti- Francisco, USA; 1:50). Basocellular carcinoma and gastric mucosa were used as positive control for Shh, SMO, Gli1 and PTCH1 antibodies. Antigen retrieval was performed by heating in a citrate buffer for Gli1 and EDTA buffer for Shh, SMO and PTCH1.
Amplification was performed with the Dako HRP system with 3,3'-diaminobenzidine revelation, and slides were counterstained with hematoxylin. All four immunohistochemical factors were tested in the training cohort and the Paris validation cohort, but only the two that were prognostic (Shh and Gli1) were tested in the Marseille validation cohort. Non specific rabbit or mouse IgG antibodies were used as negative control.
Immunohistochemistry scoring
TMA slide images were captured as high-resolution digital files. Evaluation of staining was done independently by one specialist pancreatic pathologist (P.D.) and 2 translational researchers experienced in pancreatic histopathology (R.M. and A.C.) blinded to the clinicopathological and outcome data. Any discrepancies were resolved by consensus after conferencing. The percentage of stained cells, cellular staining localization (nuclear for Gli1, cytoplasmic for Shh, membranous for SMO and PTCH1) and staining intensities (0-2) were assigned. A semi-quantitative scale based on the distribution of staining in malignant cells was used: low staining was defined as staining intensity 0 in > 95% tumor cells; high staining was defined as staining intensity 2 in > 50% tumor cells; moderate staining was assigned to the remaining cases. Each immunohistochemical factors were categorized as low (staining intensity = 0 or 1) or high (staining intensity = 2) for statistical analyses.
Tumor Stromal density
Sections were stained with a pricosirius red solution for the visualization of collagen deposits.
A representative slide of the tumor was selected by a pathologist and the quantification was done on the whole slide for each sample. We determined the stromal index by adjusting the stromal area to the proportion of tumor cells area by using the Metamorph image-analysis system (Metamorph 7.0, Molecular Devices). Morphometric analysis was carried out by two independent examiners blinded to patient outcome and biomarkers assessment.
Ethics
The study protocol was approved by the institutional review board of each participating hospitals. Written informed consent was obtained from all patients included in the prospective cohort (second validation cohort).
Statistical Analysis
Overall survival (OS) was measured as the time from the date of surgery to the time of last follow-up or death of any cause. Disease-free survival was defined as the time from surgery to the first disease-free failure event (local or distant disease relapse or death). The cut-off date for analysis was September 30, 2010. Follow-up was calculated using the reverse Kaplan- was used to compare continuous variables. Median survival was estimated using the KaplanMeier method, and the difference was tested using the log-rank test. Clinicopathological variables analyzed with a p-value < 0.05 on log-rank test were entered into Cox proportional hazards multivariate analysis. The 4 biomarkers and known prognostic factors for resected PDAC: resection margins, nodal status, tumor differentiation and T stage were included in multivariate models whatever their p-value in univariate analysis. All multivariate Cox models were built according to the rule of 10 events per variable (22) . The models assumptions were verified by graphical methods.
The predictive accuracy for multivariate models was examined by calculating the Harell concordance index (C-index). Results of Harrell C index range from 0.5 (no discrimination for predicting survival) to 1.0 (perfect discrimination).
All data analyses were carried out according to a prespecified analysis plan. The prognostic values of the immunohistochemical factors were evaluated in the Brussels cohort (n=237).
The prognostic model and the cut-off points evaluated in the training sample were then separately applied to two-independent validation samples of 234 (Paris cohort) and 96 (Marseille cohort) patients.
For investigating the predictive effect of the immunohistochemical (IHC) factors, interactions between adjuvant therapy and the factors Shh, Gli1, SMO, and PTCH1 were examined. This was done for each of these factors, including the respective factor and separate treatment effects for both values (low and high) of the interesting factor, respectively. The interaction tests between each IHC factors and the administration of adjuvant therapy were performed using the Cox model to calculate the HRs with 95% CIs.
In the absence of previous data allowing anticipating an expected rate of high and low staining for each of the IHC factors, no formal sample size evaluation has been done.
All significant tests were two-sided and all used a 5% level of significance. Statistical analyses were performed using SPSS software (version 18.0; SPSS, Chicago, Il).
Research. 
RESULTS
Cohort Characteristics
A total of 721 patients were assessed for the eligibility, and 567 were considered for this translational study. The majority of the patients have received an adjuvant therapy and most of them a gemcitabine-based regimen.
Brussels training cohort:
The cohort of 237 patients consisted of 127 (53.6%) men and 110 women. The median age at diagnosis was 63 years. The median follow-up was 53.9 months.
The median DFS and OS was 13.5 months and 26.8 months respectively, with a 5-year survival rate of 26.4%.
Paris validation cohort:
The cohort of 234 patients consisted of 139 (59.4%) men and 95 women followed during a median time of 57.3 months. The median age at diagnosis was 64 years. The median DFS and OS was 14.7 months and 30.4 months, respectively with a 5-year survival rate of 28.7%. Adjuvant therapy was more frequently administered (73.4%) than in the validation set (62%), p = 0.03.
Marseille validation cohort:
Most patients who underwent surgery were men (56.3%). The median time of follow-up was shorter than in the 2 aforementioned cohorts with a median time of 24.9 months. The median DFS and OS was 22.1 months and 26.6 months, respectively. Characteristics of the three cohorts are listed in table 1 and a detailed description of the patients flow was provided in the Data Supplement (Supplementary figure S1).
Clinicopathologic and immunohistological factors
Each IHC factor was assessed in >95% of the tumors. A good interobserver agreement for (table 1, table 2, Supplementary table S3 and figure 1 ).
The Combined Shh and Gli1 abundance stratify within lymph node status
For complementary identification of patient subgroups with the best and worst outcomes, we categorized patients according to their combined Shh and Gli1 levels. In the Brussels training set, patients with low Shh and Gli1 levels experienced the best outcomes (median OS=45.1 months; HR set at 1.0). In contrast, patients with both Shh high and Gli1 high levels had the worst outcomes (median OS=14. We examined whether Gli1, PTCH1, SMO and Shh abundance predict the benefit of adjuvant therapy. The interaction test was non significant for all the four markers evaluated both in the training and the Paris validation sets (Supplementary table S5 A dense stroma is characteristic of PDACs, and this dynamic compartment is critically involved in tumorigenesis (2) . Hh signaling has been shown to play a functionally important role in the genesis of PDAC and in the aggressive phenotype of this cancer (3) (4) (5) (6) (7) (13) (14) (15) (16) (17) .
Canonical Hh signaling operates in a paracrine fashion (3) (4) (5) (6) (7) 17) , contrasting with earlier work which focused on an autocrine role for Shh (12, 23 mice treated with the gemcitabine and the SMO inhibitor saridegib exhibited a greater increase in survival relative to gemcitabine alone due to stroma depletion and a higher vascular density resulting in a better delivery of gemcitabine to tumor cells (24) . A growing body of evidence suggests a cell autonomous non canonical Gli1 regulation through KRAS and TGF-β pathways in pancreatic cancer cells that distinct from the Hh ligand dependant paracrine effect on the tumor stroma (7, 18) . Gli1 expression is essential for PDAC cells survival and facilitates cells migration and invasion by promoting the epithelial to mesenchymal transition (EMT) process (18) (19) (20) 25) .
In aggregate, the present study strengthened the consistency of these preclinical data: in multivariate analysis, Shh and Gli1 were independent negative prognostic biomarkers of DFS and OS. The combination of these 2 biomarkers was more informative than the separate evaluation of each one suggesting that an optimized prognostic algorithm should include both biomarkers, with Shh status weighted more heavily than Gli1 status. Importantly, the prognostic value of these two biomarkers was confirmed in two independent cohorts of patients with a similar discriminating magnitude effect between the different cohorts. In addition, these concordant results in the three cohorts provided evidence that these IHC biomarkers were generally applicable to patients with PDAC independent of differences in clinical practice. Furthermore, these two biomarkers are independent of the major clinical features known to influence prognosis and could serve as an adjunct to current staging systems. Importantly, no interaction was observed between Gli1, Shh and adjuvant treatment activity making sure that this confounding factor did not affect our relationship between Gli1, Shh and patients' outcome.
Although there is possibility of bias associated with retrospective studies, our study is strengthened by the large number of patients and the two independent replication cohorts. 
pattern. Whether these two robust and easy applicable biomarkers provide sufficient prognostic information requires prospective evaluation in randomized clinical trials.
The prognostic significance of Shh and Gli1 was further strengthened by their ability to stratify within a currently validated prognostic factor. Patients with positive LN disease with low levels of Shh and Gli1 experienced similar outcomes than patients with negative LN.
The ability of these biomarkers to prognosticate within tumors with positive LN has a particularly important value, because this population represents 80% of the resected PDAC patients.
Our study showed that the Hh pathway is not uniformly active or pathogenic in all cases of PDAC and those inter-individual differences in the Hh pathway activation may contribute to the variable outcomes in PDAC. Patients with a low tumor expression for both Shh and Gli-1 experienced the best outcome. The prognostic value of Shh could be partially explained by its influence on the desmoplastic reaction (3-7, 13-17). SMO overexpression was frequently observed in pancreatic stellate cells and it has been shown that these cells are responsive to stimulation with Shh suggesting that the desmoplastic response mediated by the Hh signaling is depending on the ability of PDAC cells to produce Shh (4, 17) . Our findings support this hypothesis: (i) Shh was positively correlated to the SI, (ii) the SI was significantly higher in Shh high than in Shh low tumors and (iii) a high SI was a negative independent prognosticator for both the DFS and the OS. Overall, our results also support evidence that anti-Hh therapies targeting stroma depletion should be restricted to high Shh PDACs.
Despite the strong biological data supporting Hh inhibition in PDAC, two recent studies failed to demonstrate any additional benefit of SMO inhibitors (saridegib and vismodegib) in unselected metastatic PDAC patients compared with placebo (26, 27) . Furthermore, in the KPC model of pancreatic cancer, deletion of Shh induced stroma depletion and resulted in a undifferentiated aggressive tumor phenotype suggesting a protective role of Shh and the desmoplastic reaction (28) . At the contrary, our findings support a deleterious effect of Shh 
